Serum YKL-40 and gestational diabetes – an observational cohort study

Dorte Gybel-Brask, Julia S. Johansen, Ib J. Christiansen, Lillian Skibsted, Estrid V.S. Høgdall

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


To examine serum YKL-40 in women developing gestational diabetes mellitus (GDM). In the present large observational cohort study of 1179 pregnant women, we determined serum YKL-40 four times during pregnancy (at gestational age 12, 20, 25, and 32 weeks). Pregnancy outcome was obtained from medical records. Sixty-eight women (5.8%) developed GDM. Serum YKL-40 increased from gestational age (GA) 12 weeks and the following weeks in the women who developed GDM and was independent of BMI, parity, and maternal age (OR = 2.69, 95% CI: 1.45–5.00, p = 0.002). No association was found between serum YKL-40 and the oral glucose tolerance test results. In conclusion, YKL-40 significantly increased in pregnant women with GDM compared with women without GDM, probably reflecting the low-grade inflammation of GDM. However, we did not find an association between serum concentrations of YKL-40 in early pregnancy and the development of GDM and thus we conclude that YKL-40 alone is not usable as a biomarker for early prediction of GDM.

Sider (fra-til)770-775
Antal sider6
Udgave nummer9
StatusUdgivet - 1 sep. 2016

Fingeraftryk Udforsk hvilke forskningsemner 'Serum YKL-40 and gestational diabetes – an observational cohort study' indeholder.